Replies to post #408472 on Anavex Life Sciences Corp (AVXL)

[kevindenver]

Yes... and more analysis from the other trials too.

So what you are saying is that we need the full data set from the company for the Alzheimer’s p2/3 trial for us to reach fair value?

The market down turn is not a defence of Anavex, is a factual description of a market condition that impacts the value of an asset class (equity) and/or sector constituents.

and yes market participants will react differently to different companies presenting similar data based on trust and experience of the company.

[Investor2014]

Biogen and there AD trials may have many fault, but incomplete data presentations is not one of them.

If Biogen published the same press release that we did in early December they would have gone up tremendously.

If Biogen presented their TLR the way Anavex presented their P2b/3 AD data, then removed the slides and kept stum for over 3 months - guess what, their share value would not realise its full potential.